Efficacy and Safety of the Chinese Patent Medicine Yuquan Pill on Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis

Table 3

Subgroup analysis for outcomes.

	Number of comparisons	Results	value for overall effect	I^2	value for subgroup difference
FBG		WMD (95%CI)
All comparisons	9	−0.84 [−1.10, −0.58]	<0.00001	49%
Age					0.14
<50 y	5	−0.94 [−1.17, −0.71]	<0.00001	49%
≥50 y	4	−0.67 [−0.95, −0.38]	<0.00001	47%
Different control treatment					0.31
Metformin	3	−0.68 [−1.03, −0.34]	0.0001	67%
Other treatments	6	−0.89 [−1.10, −0.68]	<0.00001	42%
2hPG
All comparisons	8	−1.39 [−1.58, −1.20]	<0.00001	29%
Age					0.19
<50 y	4	−1.60 [−1.91, −1.29]	<0.00001	0%
≥50 y	4	−1.38 [−1.47, −1.29]	<0.00001	43%
Different control treatment					0.64
Metformin	2	−1.53 [−1.93, −1.13]	<0.00001	0%
Acarbose	2	−1.38 [−1.48, −1.29]	<0.00001	73%
Other treatments	4	−1.49 [−1.79, −1.19]	<0.00001	43%
Course of treatment					0.95
<8 w	3	−1.39 [−1.49, −1.30]	<0.00001	0%
≥8 w	5	−1.38 [−1.65, −1.12]	<0.00001	56%
HbA1c
All comparisons	6	−0.87 [−1.26, −0.49]	<0.00001	78%
Age					0.11
<50 y	3	−1.09 [−1.38, −0.80]	<0.00001	10%
≥50 y	3	−0.61 [−1.12, −0.11]	0.02	78%
Different control treatment					0.74
Metformin	3	−0.84 [−1.31, −0.37]	0.0005	74%
Other treatments	3	−1.01 [−1.86, −0.15]	0.02	83%
Duration of disease					0.26
<10 y	5	−0.82 [−1.22, −0.42]	0.0004	81%
≥10 y	1	−1.60 [−2.91, −0.29]	0.02	NA
TC
All comparisons	3	−0.50 [−0.61, −0.39]	<0.00001	0%
Age					0.20
<50 y	1	−1.02 [−1.83, −0.21]	0.01	NA
≥50 y	2	−0.49 [−0.60, −0.38]	<0.00001	0%
Course of treatment					0.97
<8 w	1	−0.50 [−0.68, −0.32]	<0.00001	NA
≥8 w	2	−0.50 [−0.64, −0.36]	<0.00001	40%
CRP
All comparisons	4	−0.58 [−0.88, −0.28]	0.0005	83%
Age					0.84
<50 y	1	−0.55 [−0.69, −0.41]	<0.00001	NA
≥50 y	3	−0.61 [−1.18, −0.05]	0.03	88%
Safety					0.05
No adverse effects	1	−1.13 [−1.49, −0.77]	<0.00001	NA
Adverse effects occurring	3	−0.62 [−0.97, −0.26]	0.0007	89%
Region					0.81
Henan province	2	−0.81 [−1.38, −0.25]	0.005	88%
Other provinces	2	−0.69 [−1.52, 0.14]	0.10	94%
Overall effective rate		RR (95%CI)
All comparisons	6	1.21 [1.12, 1.31]	<0.00001	0%
Age					0.90
<50 y	2	1.22 [1.08, 1.38]	0.001	0%
≥50 y	4	1.21 [1.09, 1.34]	0.0002	0%
Different control treatment					0.79
Metformin	3	1.20 [1.08, 1.34]	0.001	0%
Other treatments	3	1.23 [1.10, 1.37]	0.0003	0%
Course of treatment					0.27
<8 w	1	1.10 [0.92, 1.33]	0.30	NA
≥8 w	5	1.24 [1.14, 1.35]	<0.00001	0%
Region					0.50
Henan province	2	1.18 [1.06, 1.30]	0.002	0%
Other provinces	4	1.24 [1.11, 1.38]	0.0001	0%

FBG, fasting blood glucose; 2hPG, two-hour postprandial glucose; HbA1c, glycosylated hemoglobin; TC, total cholesterol; CRP, c-reactive protein; Y, year; W, week.